Chelohart is a heart peptide bioregulator, a short-chain peptide complex made from myocardial tissue and labeled A-14 in the Khavinson system. It’s studied for one job in particular: supporting the heart muscle cells that keep your heart pumping across a lifetime.
That focus is what makes it interesting. Most cardiovascular supplements work on blood flow, cholesterol, or antioxidants. Chelohart aims one level deeper, at the cells that do the actual pumping.
This guide walks through what the peptide is, what the research shows, and how it differs from the vascular bioregulators it often gets confused with.
Key Takeaways
The Short Version
Chelohart is a myocardium-derived peptide bioregulator studied for supporting heart muscle cell metabolism and healthy cardiovascular aging.
Its proposed benefit comes from tissue-specific signaling, where short heart peptides may help cardiac cells hold normal function as they age.
The strongest human longevity data in this field comes from related peptide bioregulators, while Chelohart’s own evidence is mainly cell-based.
Quality matters more than marketing here, so look for third-party testing and a transparent, single-complex formula.
The Heart Cell That Barely Renews Itself
Your heart runs on cardiomyocytes, the muscle cells that contract roughly 100,000 times a day. Unlike skin cells or gut cells, adult cardiomyocytes almost never divide, so the heart has very little natural capacity to grow new ones.
That single fact shapes why a heart-specific peptide draws attention. If cardiac cells can’t easily be replaced, then keeping the existing ones healthy becomes the whole game.
Chelohart is built around the A-14 peptide complex, extracted from heart muscle tissue. The idea behind peptide bioregulators is tissue specificity: short peptides pulled from one organ are studied for supporting that same organ, and different sequences steer cells in different directions [5].
If you’re new to this category, our primer on what peptide bioregulators are covers the basics, and the story of the Khavinson peptide research explains where these compounds came from. This article stays focused on the heart.
What Cardiac Peptide Research Has Found
Research on cardiac peptides points in a promising direction, and it splits cleanly into two tiers: what happens in cells, and what happens in people. Reading them separately is the honest way to judge the peptide, and it’s also where the real story lives.
In the lab: heart cells and gene signaling
Most Chelohart research sits at the cell and molecular level. Short peptides like these are studied for their ability to reach the cell nucleus and influence which genes switch on, an effect researchers describe as peptidergic regulation of gene activity [4][6].
For the heart, that’s the mechanism of interest. In cell-based research, cardiac peptides have been examined for supporting cardiomyocyte metabolism and helping heart cells maintain their normal structure and function.
A 2023 review in Cells looked specifically at how peptide regulation may influence senescence and inflammatory signaling in cardiovascular cells, the kind of low-grade decline that builds up as the heart ages [1]. It’s early work, but it’s aimed squarely at the right target.
In people: the cardiovascular longevity trials
Here’s where the bioregulator field earns a second look. In a 12-year controlled study, elderly coronary patients who took a related peptide bioregulator alongside standard care showed a twofold lower rate of cardiovascular mortality than the control group [3].
A separate 15-year follow-up reported that long-term peptide treatment slowed cardiovascular aging and was linked to lower overall mortality [2].
One honest note: neither trial tested Chelohart itself. Both used a related pineal-derived bioregulator from the same research program. But they show this approach has produced genuine long-term human cardiovascular data, which is more than most novel peptides can claim. Foundational work on tissue-specific short peptides set the stage for the heart-focused compounds that followed [5].
Chelohart vs. Ventfort: Heart Muscle or Blood Vessels?
Chelohart and Ventfort often get grouped as cardiovascular peptides, but they target different tissue. Chelohart is made from heart muscle, while Ventfort is made from blood vessel tissue, so they support different parts of the same system.
| Factor | Chelohart (A-14) | Ventfort (A-3) |
|---|---|---|
| Source tissue | Heart muscle | Blood vessels |
| Main focus | Cardiomyocyte metabolism and function | Endothelial and vascular health |
| Best for | Heart muscle and cardiac aging support | Circulation and blood vessel support |
| Fits alongside | A broader cardiovascular routine | A broader cardiovascular routine |
If circulation and vessel health are your priority, Ventfort, the blood vessel bioregulator, is the closer match, and you’ll find it as BioBloodVessels (Ventfort). Many people interested in cardiovascular aging look at both, since one supports the muscle and the other supports the plumbing.
Fitting Chelohart Into a Heart-Smart Routine
Chelohart is designed to slot into a daily longevity routine, not to replace the basics that carry the most weight for heart health. Sleep, movement, blood pressure, and diet still do the heavy lifting, and the peptide is meant to support that foundation.
Each BioHeart capsule delivers 40 mg of the A-14 heart peptide complex. Peptide bioregulators are typically taken in courses rather than continuously, so follow the product label for timing and cycle length unless your clinician advises otherwise.
It tends to suit a few kinds of people:
- Adults focused on cardiovascular aging who already have the fundamentals in place.
- Bioregulator users who want to add heart-tissue support to an organ-system stack.
- People who prefer a single, clearly labeled peptide complex over a crowded blend.
You can browse the full range of peptide bioregulators if you’re building a multi-tissue routine.
One safety point worth stating clearly: if you take blood pressure medication or a blood thinner, or you’re managing any heart condition, talk with your clinician before adding Chelohart. This is about coordinating with your existing care, not a warning against the peptide itself.
Buying a Heart Peptide You Can Verify
The single biggest difference between heart peptide products is quality, not the claims on the label. Because these are advanced ingredients, verification is where a trustworthy brand separates itself.
Look for three things:
- Third-party testing with a Certificate of Analysis you can actually see.
- A transparent formula that lists the exact peptide complex and amount per capsule.
- Clean manufacturing standards rather than vague “premium” language.
BioHeart is built to that standard, and you can read more about how peptide quality is verified on our science of peptides page. When the ingredient is this specialized, proof should come before the promise.
Frequently Asked Questions
Is Chelohart the same as Cardiogen?
They’re related but not identical. Chelohart is the natural heart peptide complex extracted from myocardial tissue, while Cardiogen is a shorter synthesized peptide studied as a research tool. Chelohart is the form used in bioregulator supplements.
How is Chelohart taken?
Chelohart is usually taken as a capsule in courses, often around 30 days, with repeat courses spaced across the year. Follow the product label for the exact protocol.
Can Chelohart be taken with heart medication?
Talk to your clinician first. Chelohart is not a substitute for prescribed heart medication, and anyone managing a cardiovascular condition should coordinate any new supplement with their care team.
Is Chelohart a replacement for cardiovascular care?
No. It’s designed to support healthy cardiovascular aging as part of a routine, not to treat, prevent, or manage heart disease. Standard medical care and lifestyle habits remain the foundation.
Can Chelohart be stacked with other bioregulators?
Yes, bioregulators are often combined to cover multiple tissues. Pairing a heart peptide with a vascular one is a common approach for people focused on cardiovascular aging.
Read More From the BioLongevity Blog
- Best Longevity Supplements: What to Look For
- Gotratix Peptide Benefits: The Muscle Bioregulator
- Vesugen Peptide Benefits: The Vascular Tripeptide
Ready to add heart-tissue support to your longevity routine? BioHeart โ A-14 Heart Peptide Bioregulator (Chelohart) delivers a transparent 40 mg peptide complex, third-party tested and single-ingredient, so you know exactly what you’re taking and can verify it before you do.
Ask a qualified clinician before starting any supplement if you are pregnant, nursing, taking medication, or managing a medical condition.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. Senescence-Associated Secretory Phenotype of Cardiovascular System Cells and Inflammaging: Perspectives of Peptide Regulation. Cells. 2023;12(1):106. https://doi.org/10.3390/cells12010106
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide Geroprotector from the Pituitary Gland Inhibits Rapid Aging of Elderly People: Results of 15-Year Follow-Up. Bulletin of Experimental Biology and Medicine. 2011;151(3):366-369. https://doi.org/10.1007/s10517-011-1332-x
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyuk-Shcheglova IA. Geroprotective Effect of Epithalamine (Pineal Gland Peptide Preparation) in Elderly Subjects with Accelerated Aging. Bulletin of Experimental Biology and Medicine. 2006;142(3):356-359. https://doi.org/10.1007/s10517-006-0365-z
- Anisimov VN, Khavinson VKh. Peptide Bioregulation of Aging: Results and Prospects. Biogerontology. 2010;11(2):139-149. https://doi.org/10.1007/s10522-009-9249-8
- Khavinson VKh. Peptides and Ageing. Neuro Endocrinology Letters. 2002;23 Suppl 3:11-144. https://pubmed.ncbi.nlm.nih.gov/12374906/
- Kuznik BI, Linkova NS, Khavinson VKh. Heat Shock Proteins: Age-Related Changes, Development of Thrombotic Diseases, and Peptidergic Regulation of Genes. Advances in Gerontology. 2011;24(1):37-45. https://pubmed.ncbi.nlm.nih.gov/22550861/